Heart Failure - Bayer
Heart Failure - Bayer supports clinicians with education on mildly reduced or preserved ejection fraction heart failure to build understanding of disease burden, care standards, treatment gaps, and safety.
Funder: Bayer
Due Dates: Monthly review (complete proposals)
Funding Amounts: Award amount and duration not specified
Summary: Supports clinician education on HFmrEF and HFpEF disease burden, standards of care, treatment gaps, MRA evidence, and safety.
Key Information: Proposals must comply with commercial-support standards and include the provider’s latest accreditation letter and status.
Description
Bayer’s Heart Failure educational grant supports medical education on heart failure with mildly reduced or preserved ejection fraction (HFmrEF and HFpEF), defined for this program as left ventricular ejection fraction of at least 40%. Intended audiences include primary care providers, nurses, physician assistants, cardiologists, endocrinologists, nephrologists, and internal medicine clinicians. Educational priorities include contemporary disease definitions, epidemiology, clinical outcomes, pathophysiology, co-morbid conditions, and current standards of care.
The program also emphasizes treatment gaps, real-world use of recommended therapies, residual risk, and the unique properties of non-steroidal mineralocorticoid receptor antagonists (MRAs) compared with steroidal agents. Supported education addresses efficacy evidence from FINEARTS-HF and relevant subanalyses, FINEHEART, and safety and tolerability.
